Fig. 6From: Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphomaCombination treatment affected mTOR pathway. All cell lines were treated with NVP-Bez235 and lenalidomide for 72Â h. Cell lysis was determined by immunoblotting to identify the protein mTOR, p-mTOR, p70S6K, p-p70S6K, 4EBP1, and p-4EBP1Back to article page